BR0207854A - Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido - Google Patents

Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido

Info

Publication number
BR0207854A
BR0207854A BR0207854-6A BR0207854A BR0207854A BR 0207854 A BR0207854 A BR 0207854A BR 0207854 A BR0207854 A BR 0207854A BR 0207854 A BR0207854 A BR 0207854A
Authority
BR
Brazil
Prior art keywords
antibody
expression technology
hybrid
proteins containing
antibody moiety
Prior art date
Application number
BR0207854-6A
Other languages
English (en)
Inventor
Stephen D Gillies
Jeffrey Way
Kin-Ming Lo
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR0207854A publication Critical patent/BR0207854A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

"TECNOLOGIA DE EXPRESSãO PARA PROTEìNAS CONTENDO UMA PORçãO DE ANTICORPO DE ISOTIPO HìBRIDO". A presente invenção refere-se métodos e composições para eficientemente expressar as proteínas de fusão de anticorpo. As proteínas de fusão de anticorpo da invenção incluem uma porção de anticorpo híbrido contendo seq³ências de mais do que um tipo de anticorpo e/ou seq³ências de anticorpo mutantes. As proteínas de fusão de anticorpo híbrido da invenção podem ser produzidas em níveis elevados e podem combinar propriedades funcionais características de tipos de anticorpos diferentes além das propriedades funcionais de uma porção de não-anticorpo.
BR0207854-6A 2001-03-07 2002-03-07 Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido BR0207854A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27409601P 2001-03-07 2001-03-07
PCT/US2002/007011 WO2002072605A2 (en) 2001-03-07 2002-03-07 Expression technology for proteins containing a hybrid isotype antibody moiety

Publications (1)

Publication Number Publication Date
BR0207854A true BR0207854A (pt) 2004-08-24

Family

ID=23046749

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207854-6A BR0207854A (pt) 2001-03-07 2002-03-07 Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido

Country Status (17)

Country Link
US (2) US7148321B2 (pt)
EP (1) EP1366067B1 (pt)
JP (1) JP4234438B2 (pt)
KR (2) KR100900176B1 (pt)
CN (1) CN1330664C (pt)
AU (1) AU2002248571B2 (pt)
BR (1) BR0207854A (pt)
CA (1) CA2440221C (pt)
DK (1) DK1366067T3 (pt)
ES (1) ES2393733T3 (pt)
HU (1) HUP0303428A2 (pt)
MX (1) MXPA03008031A (pt)
PL (1) PL206701B1 (pt)
PT (1) PT1366067E (pt)
RU (1) RU2003129528A (pt)
WO (1) WO2002072605A2 (pt)
ZA (1) ZA200307792B (pt)

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69824039T2 (de) 1997-12-08 2005-08-18 Lexigen Pharmaceuticals Corp., Lexington Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
PL343462A1 (en) * 1998-04-15 2001-08-13 Lexigen Pharm Corp Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
ATE369384T1 (de) * 1999-05-19 2007-08-15 Emd Lexigen Res Ct Corp Expression und export von interferon-alpha proteinen als fc fusionsproteine
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
BR0013231A (pt) * 1999-08-09 2002-07-23 Lexigen Pharm Corp Complexos citocina-anticorpo múltiplos
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
ES2269366T3 (es) * 2000-02-11 2007-04-01 Merck Patent Gmbh Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos.
DE60129695T2 (de) * 2000-06-29 2008-06-05 Merck Patent Gmbh Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
DE10045591A1 (de) * 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
BR0207854A (pt) 2001-03-07 2004-08-24 Merck Patent Gmbh Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
DE60239454D1 (de) 2001-05-03 2011-04-28 Merck Patent Gmbh Rekombinanter, tumorspezifischer antikörper und dessen verwendung
ES2381025T3 (es) 2001-12-04 2012-05-22 Merck Patent Gmbh Inmunocitocinas con selectividad modulada
JP4494977B2 (ja) * 2002-12-17 2010-06-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
CA2551915C (en) 2003-12-30 2015-06-23 Merck Patent Gesellschaft Mit Beschraenkter Haftung Il-7 fusion proteins
PT1699821E (pt) 2003-12-31 2012-08-23 Merck Patent Gmbh Proteína de fusão fc-eritropoietina com farmacocinética melhorada
EP1702069A2 (en) 2004-01-05 2006-09-20 EMD Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
WO2005070967A2 (en) * 2004-01-22 2005-08-04 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US8518403B2 (en) * 2004-07-16 2013-08-27 Amgen Research (Munich) Gmbh Expression-enhanced polypeptides
RU2437893C2 (ru) 2004-12-09 2011-12-27 Мерк Патент Гмбх Варианты il-7 со сниженной иммуногенностью
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
DK1912675T3 (en) 2005-07-25 2014-03-24 Emergent Product Dev Seattle B-cell reduction using specific and cd37-cd20-specific binding molecules
WO2007024743A2 (en) * 2005-08-19 2007-03-01 Centocor, Inc. Proteolysis resistant antibody preparations
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
WO2007067828A2 (en) * 2005-10-24 2007-06-14 Centocor, Inc. Glp-2 mimetibodies, polypeptides, compositions, methods and uses
JP2009521909A (ja) 2005-12-30 2009-06-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ＩＬ−６とＩＬ−６Ｒαの複合体のｇｐ１３０への結合を阻害する抗ＩＬ−６抗体
JP2009521912A (ja) 2005-12-30 2009-06-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 低減された免疫原性を有する抗ｃｄ１９抗体
PT1966238E (pt) 2005-12-30 2012-07-31 Merck Patent Gmbh Uso de hsp70 como um regulador de atividade enzimática
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
TW200738752A (en) 2006-01-31 2007-10-16 Bayer Schering Pharma Ag Modulation of MDL-1 activity for treatment of inflammatory disease
KR100949982B1 (ko) * 2006-03-30 2010-03-29 엘지전자 주식회사 비디오 신호를 디코딩/인코딩하기 위한 방법 및 장치
DK3056568T3 (da) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
ES2654040T3 (es) 2006-03-31 2018-02-12 Chugai Seiyaku Kabushiki Kaisha Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos
JP2009539413A (ja) 2006-06-12 2009-11-19 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド エフェクター機能を有する単鎖多価結合タンパク質
JP2009542592A (ja) * 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法
CA2681935A1 (en) * 2007-03-30 2008-10-09 Baker Medical Research Institute Treatment of obesity
NZ581395A (en) * 2007-05-14 2012-08-31 Biogen Idec Inc Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
JP5168538B2 (ja) * 2007-05-24 2013-03-21 アボットジャパン株式会社 抗体−抗体コンジュゲートと抗体測定系診断薬への応用
AU2013263716B2 (en) * 2007-06-01 2016-01-07 Gliknik Inc Immunoglobulin constant region FC receptor binding agents
CN107011445B (zh) 2007-06-01 2021-06-29 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
CA2691374A1 (en) 2007-06-29 2009-01-08 Asubio Pharma Co., Ltd. Recombinant c-terminal .alpha.-amidating enzyme derivative
CN101990439A (zh) * 2007-07-06 2011-03-23 特鲁比昂药品公司 具有置于c末端的特异性结合结构域的结合肽
BRPI0814465B1 (pt) * 2007-07-26 2021-11-23 Novagen Holding Corporation Proteína de fusão, dímero, método para produzir uma proteína de fusão, linhagem de célula, usos de uma proteína de fusão e de uma composição farmacêutica e composição farmacêutica
AU2008298904B2 (en) 2007-09-14 2014-10-16 Amgen Inc. Homogeneous antibody populations
CN106519025B (zh) 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
CL2008002886A1 (es) 2007-09-26 2009-12-04 Chugai Pharmaceutical Co Ltd Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende.
BRPI0821110B8 (pt) 2007-12-05 2021-05-25 Chugai Pharmaceutical Co Ltd anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
US8557243B2 (en) * 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
AU2008346734A1 (en) * 2008-01-03 2009-07-16 The Scripps Research Institute Antibody targeting through a modular recognition domain
US8454960B2 (en) * 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8574577B2 (en) * 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557242B2 (en) * 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
ES2368700T3 (es) 2008-04-11 2011-11-21 Emergent Product Development Seattle, Llc Agente inmunoterapéutico para cd37 y combinación con un agente quimioterapéutico bifuncional del mismo.
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
CA2759333A1 (en) 2009-04-22 2010-10-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
MA33405B1 (fr) 2009-05-15 2012-07-03 Chugai Pharmaceutical Co Ltd Anticorps anti-axl
WO2011037158A1 (ja) 2009-09-24 2011-03-31 中外製薬株式会社 抗体定常領域改変体
BR112012010252A2 (pt) * 2009-10-29 2016-12-06 Janssen Biotech Inc variantes de glicosilação de anticorpo
BR112012010202A2 (pt) * 2009-11-02 2015-09-22 Univ Washington molécula de nuclease hibrida polipeptideo dimerico, composição farmacêutica molécula de acido nucleico vetor de expressão recombinante célula hospedeira transformada metodo para preparar a molécula de nuclease e metodo para tratar ou previnir uma condição associada com uma imune anormal
WO2011064758A2 (en) * 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
CN101870735B (zh) * 2010-06-02 2013-06-12 北京精益泰翔技术发展有限公司 一种新型高糖基化***免疫融合蛋白
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
CN103154036B (zh) 2010-07-28 2016-05-11 格利克尼克股份有限公司 天然人蛋白片段的融合蛋白以产生有序多聚化免疫球蛋白fc组合物
US8883134B2 (en) 2010-10-20 2014-11-11 Handok Pharmaceuticals, Inc. Human interleukin-1 receptor antagonist—hybrid Fc fusion protein
HUE033008T2 (hu) * 2011-04-13 2017-11-28 Bristol Myers Squibb Co FC fúziós proteinek, amelyek tartalmaznak új linkereket
PL2704737T3 (pl) 2011-04-29 2018-07-31 University Of Washington Terapeutyczne kompozycje nukleaz i sposoby
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
EP3626739A1 (en) 2011-06-24 2020-03-25 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
CN103857700A (zh) * 2011-08-26 2014-06-11 梅里麦克制药股份有限公司 串联fc双特异性抗体
WO2013049254A1 (en) * 2011-09-26 2013-04-04 Jn Biosciences Llc Hybrid constant regions
US9382319B2 (en) 2011-09-26 2016-07-05 Jn Biosciences Llc Hybrid constant regions
CA2899433A1 (en) * 2012-01-27 2013-08-01 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
WO2013156054A1 (en) 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
US9809641B2 (en) 2012-04-23 2017-11-07 Nrl Pharma, Inc. Lactoferrin fusion protein and method for preparation thereof
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
US20160009824A1 (en) 2013-03-15 2016-01-14 Merck Patent Gmbh Tetravalent bispecific antibodies
EA201890895A1 (ru) 2013-03-15 2019-02-28 Зинджения, Инк. Мультивалентные и моновалентные мультиспецифические комплексы и их применение
CA2909576C (en) 2013-04-19 2023-07-18 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
US20150038682A1 (en) * 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
JP6623353B2 (ja) 2013-09-13 2019-12-25 ベイジーン スウィッツァーランド ゲーエムベーハー 抗ｐｄ−１抗体並びにその治療及び診断のための使用
BR112016006197B1 (pt) 2013-09-27 2023-04-11 Chugai Seiyaku Kabushiki Kaisha Método para produzir um anticorpo biespecífico de polipeptídeos
US10988745B2 (en) 2013-10-31 2021-04-27 Resolve Therapeutics, Llc Therapeutic nuclease-albumin fusions and methods
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
DK3105246T3 (da) 2014-02-10 2021-06-14 Merck Patent Gmbh Målrettet TGF-beta-inhibering
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP6851200B2 (ja) 2014-03-05 2021-03-31 ユーシービー バイオファルマ エスアールエル 多量体Ｆｃタンパク質
SG11201608194VA (en) * 2014-04-03 2016-10-28 Igm Biosciences Inc Modified j-chain
CA2945305C (en) 2014-04-10 2023-10-17 Seattle Children's Hospital (dba Seattle Children's Research Institute) Method and compositions for cellular immunotherapy
CN106456734A (zh) * 2014-05-29 2017-02-22 免疫医疗有限责任公司 Ox40l融合蛋白及其用途
JP6526189B2 (ja) 2014-07-03 2019-06-05 ベイジーン リミテッド 抗ｐｄ−ｌ１抗体並びにその治療及び診断のための使用
BR112017001385B1 (pt) 2014-07-22 2023-12-05 Cb Therapeutics, Inc. Anticorpo isolado ou fragmento do mesmo que liga a pd-1, uso deste, composição, polinucleotídeo isolado e vetor de expressão
KR102476226B1 (ko) 2014-08-05 2022-12-12 아폴로믹스 인코포레이티드 항-pd-l1 항체
HUE043038T2 (hu) 2014-08-11 2019-07-29 Delinia Inc Regulator T-sejteket szelektíven aktiváló, módosított IL-2-változatok autoimmun betegségek kezelésére
RS60631B1 (sr) 2014-11-21 2020-09-30 Bristol Myers Squibb Co Antitela protiv cd73 i njihova upotreba
EP3221346B1 (en) 2014-11-21 2020-09-02 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
CN107810202A (zh) 2015-02-17 2018-03-16 韩美药品株式会社 长效胰岛素或胰岛素类似物复合物
TWI805046B (zh) 2015-02-27 2023-06-11 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
EP3279216A4 (en) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha PROCESS FOR PREPARING POLYPEPTIDE HETERO OLIGOMER
EP3878857A1 (en) * 2015-04-22 2021-09-15 Biogen MA Inc. Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
WO2017004083A1 (en) * 2015-06-29 2017-01-05 The Regents Of The University Of California Methods of producing nucleic acid libraries and compositions and kits for practicing same
CA2994829A1 (en) 2015-08-07 2017-02-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific car t-cells for solid tumor targeting
EP3352760A4 (en) 2015-09-21 2019-03-06 Aptevo Research and Development LLC CD3 BINDING POLYPEPTIDES
US10618978B2 (en) 2015-09-30 2020-04-14 Igm Biosciences, Inc. Binding molecules with modified J-chain
ES2819870T3 (es) 2015-09-30 2021-04-19 Igm Biosciences Inc Moléculas de unión con cadena J modificada
US20180271998A1 (en) 2015-12-04 2018-09-27 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
WO2017115773A1 (ja) 2015-12-28 2017-07-06 中外製薬株式会社 Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
WO2017214321A1 (en) * 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CN109475536B (zh) 2016-07-05 2022-05-27 百济神州有限公司 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合
KR20230125859A (ko) 2016-08-12 2023-08-29 메르크 파텐트 게엠베하 암에 대한 조합 요법
AU2017313085A1 (en) 2016-08-19 2019-03-14 Beigene Switzerland Gmbh Use of a combination comprising a Btk inhibitor for treating cancers
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JP7142915B2 (ja) 2016-10-28 2022-09-28 株式会社Ｓ＆Ｋバイオファーマ ラクトフェリン／アルブミン融合タンパク質及びその製造方法
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
EA201991142A1 (ru) 2016-11-08 2019-10-31 Варианты il-2 для лечения аутоиммунных заболеваний
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
KR20190095929A (ko) 2016-12-09 2019-08-16 글리크닉 인코포레이티드 다합체화 스트라도머인 gl-2045의 제조 최적화
US11331372B2 (en) 2016-12-09 2022-05-17 Gliknik Inc. Methods of treating inflammatory disorders with multivalent Fc compounds
US11408005B2 (en) 2016-12-12 2022-08-09 Seattle Children's Hospital Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
CN110461847B (zh) 2017-01-25 2022-06-07 百济神州有限公司 (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
CA3066518A1 (en) 2017-06-26 2019-01-03 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
EP3650539A4 (en) * 2017-07-07 2021-08-18 Hanmi Pharm. Co., Ltd. NEW THERAPEUTIC ENZYMATIC FUSION PROTEIN AND ASSOCIATED USE
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
WO2019125732A1 (en) 2017-12-19 2019-06-27 Xencor, Inc. Engineered il-2 fc fusion proteins
CR20200392A (es) 2018-03-09 2020-11-17 Agenus Inc Anticuerpos anti-cd73 y métodos de uso de los mismos
CA3093729A1 (en) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
JP2022503959A (ja) 2018-10-03 2022-01-12 ゼンコア インコーポレイテッド Ｉｌ－１２ヘテロ二量体ｆｃ－融合タンパク質
EP3873612A2 (en) 2018-11-01 2021-09-08 Merck Patent GmbH Methods of administering anti-tim-3 antibodies
CA3117429A1 (en) 2018-11-01 2020-05-07 Merck Patent Gmbh Anti-tim-3 antibodies
US20220056135A1 (en) 2018-12-21 2022-02-24 Ose Immunotherapeutics Bifunctional anti-pd-1/sirpa molecule
US20220025050A1 (en) 2018-12-21 2022-01-27 Ose Immunotherapeutics Bifunctional molecule directed against human pd-1
CN113614109A (zh) 2018-12-21 2021-11-05 Ose免疫疗法公司 双功能抗pd-1/il-7分子
DK3883966T3 (da) 2018-12-21 2023-10-16 Ose Immunotherapeutics Humaniseret anti-human-pd-1-antistof
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
CA3141459A1 (en) 2019-05-17 2020-11-26 Xencor, Inc. Il-7-fc-fusion proteins
US11851466B2 (en) 2019-10-03 2023-12-26 Xencor, Inc. Targeted IL-12 heterodimeric Fc-fusion proteins
CA3224182A1 (en) * 2021-06-17 2022-12-22 Fapon Biotech Inc. Chimeric immunoglobulin
US20230190799A1 (en) * 2021-07-21 2023-06-22 City Of Hope Chimeric antigen receptor t cells targeting cea and anti-cea-il2 immunocytokines for cancer therapy
WO2023076927A1 (en) * 2021-10-27 2023-05-04 Anwita Biosciences, Inc. Il-2 fusion proteins, pharmaceutical compositions, and therapeutic applications
CN114835810B (zh) * 2022-03-31 2024-01-05 浙江特瑞思药业股份有限公司 一种抗pd-1纳米抗体及其应用

Family Cites Families (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US81664A (en) * 1868-09-01 Island
US193570A (en) * 1877-07-24 Improvement in washing-boards
US3529A (en) * 1844-04-10 yvolfe
US105294A (en) * 1870-07-12 Erasmus w
US147311A (en) * 1874-02-10 Improvement in electric telegraphs
US192222A (en) * 1877-06-19 Improvement in watches
US166877A (en) * 1875-08-17 Improvement in electric lights
US44423A (en) * 1864-09-27 Improved screw for music-stools
US12789A (en) * 1855-05-01 Office
US49227A (en) * 1865-08-08 Improvement in construction of railway trains and cars
US53539A (en) * 1866-03-27 Improvement in revolving fire-arms
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4469797A (en) 1982-09-23 1984-09-04 Miles Laboratories, Inc. Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4966843A (en) * 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US5082658A (en) * 1984-01-16 1992-01-21 Genentech, Inc. Gamma interferon-interleukin-2 synergism
EP0158198A1 (en) 1984-03-29 1985-10-16 Takeda Chemical Industries, Ltd. DNA and use thereof
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4667016A (en) * 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5679543A (en) 1985-08-29 1997-10-21 Genencor International, Inc. DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
US5643565A (en) 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
DE3712985A1 (de) 1987-04-16 1988-11-03 Hoechst Ag Bifunktionelle proteine
US5359035A (en) 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
EP0237019A3 (en) 1986-03-14 1988-03-09 Toray Industries, Inc. Interferon conjugate and production thereof using recombinant gene
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DK173067B1 (da) 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US4894227A (en) 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5508031A (en) 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
US4732683A (en) * 1986-12-02 1988-03-22 Biospectrum, Inc. Purification method for alpha interferon
US5019368A (en) 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
ATE120761T1 (de) 1987-05-21 1995-04-15 Creative Biomolecules Inc Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
EP0294703B1 (en) 1987-06-10 1995-05-10 Dana-Farber Cancer Institute, Inc. Bifunctional antibody constructs and method for selectively destroying cell populations
US5064646A (en) 1988-08-02 1991-11-12 The University Of Maryland Novel infectious bursal disease virus
PH26813A (en) 1987-09-02 1992-11-05 Ciba Geigy Ag Conjugates of cytokines with immunoglobulins
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5677425A (en) * 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
CA1338518C (en) 1987-09-23 1996-08-13 Joyce M. Zarling Antibody heteroconjugates for the killing of hiv-infected cells
NZ226414A (en) 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
ZA888978B (en) 1987-12-04 1990-07-25 Du Pont Immobilized interleukin 2 and interleukin 2 containing a carboxylterminal extension
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
CA1341588C (en) 1988-01-26 2009-01-06 Michel Revel Human ifn-beta2/i1-6, its purification and use
US5120525A (en) 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
IT1217724B (it) 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori
IE62463B1 (en) 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5242824A (en) 1988-12-22 1993-09-07 Oncogen Monoclonal antibody to human carcinomas
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
EP0406857B1 (en) 1989-07-07 1995-05-24 Takeda Chemical Industries, Ltd. Proteins and production thereof
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
CA2066612C (en) * 1989-09-20 1998-12-08 Stephen D. Gillies Method of producing fusion proteins
JP2983629B2 (ja) 1989-10-13 1999-11-29 キリン―アムジエン・インコーポレイテツド エリスロポエチンイソフォーム
US5856298A (en) 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
ATE369383T1 (de) 1989-12-22 2007-08-15 Hoffmann La Roche Monoklonale antikörper spezifisch für den zytotoxischen lymphozyten-reifefaktor
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
WO1991013166A1 (en) * 1990-03-02 1991-09-05 Abbott Biotech, Inc. Antibody constructs with enhanced binding affinity
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5709859A (en) 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US6072039A (en) 1991-04-19 2000-06-06 Rohm And Haas Company Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
DE69227693T2 (de) 1991-08-30 1999-07-22 Hutchinson Fred Cancer Res Hybride cytokine
US20020037558A1 (en) 1991-10-23 2002-03-28 Kin-Ming Lo E.coli produced immunoglobulin constructs
US5277375A (en) * 1991-12-04 1994-01-11 The Procter & Gamble Company Spindle for use with compressed core wound paper products
US6627615B1 (en) 1991-12-17 2003-09-30 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
EP0633929B1 (en) 1992-04-01 2004-03-03 The Rockefeller University METHOD FOR $i(IN VITRO) PROLIFERATION OF DENDRITIC CELL PRECURSORS AND THEIR USE TO PRODUCE IMMUNOGENS
WO1993024135A1 (en) * 1992-05-26 1993-12-09 Immunex Corporation Novel cytokine that binds cd30
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
CA2142007C (en) 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
DE4228839A1 (de) 1992-08-29 1994-03-03 Behringwerke Ag Verfahren zum Nachweis und zur Bestimmung von Mediatoren
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
EP1757694A3 (en) 1992-11-05 2008-02-27 Sloan Kettering Institute For Cancer Research Prostate-specific membrane antigen
US5738849A (en) 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5543297A (en) 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
KR960701988A (ko) * 1993-04-20 1996-03-28 윌리엄 에스. 로빈슨 세포내 감염원에 감염된 개체의 치료방법 및 치료물질(methods and materials for treatment of individuals infected with intracellular in-fectious agents)
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
JPH08509614A (ja) 1993-04-29 1996-10-15 アボツト・ラボラトリーズ エリスロポエチン類似体組成物および方法
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
CA2125763C (en) 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
US5609876A (en) * 1993-08-09 1997-03-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptide vaccines and associated methods for protection against feline leukemia virus
IL192290A0 (en) 1993-08-17 2008-12-29 Kirin Amgen Inc Erythropoietin analogs
EP0758390B1 (en) 1994-04-26 2007-02-28 The Children's Medical Center Corporation Angiostatin and method of use for inhibition of angiogenesis
US5837682A (en) 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5888773A (en) * 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
ES2167391T3 (es) 1994-09-16 2002-05-16 Merck Patent Gmbh Inmunoconjugados ii.
JP3429578B2 (ja) * 1994-10-31 2003-07-22 オリンパス光学工業株式会社 小型リアフォーカスズームレンズ
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US5691309A (en) 1995-01-31 1997-11-25 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5891680A (en) 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
JP3342873B2 (ja) 1995-03-10 2002-11-11 ジェネンテク・インコーポレイテッド ｇａｓ６による受容体活性化
US5719266A (en) 1995-03-17 1998-02-17 Eli Lilly And Company Anti-obesity proteins
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
JPH11508895A (ja) 1995-06-30 1999-08-03 イーライ・リリー・アンド・カンパニー 糖尿病を処置する方法
US6406689B1 (en) 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
US5854205A (en) 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US6620413B1 (en) * 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US6080409A (en) 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
CA2205757C (en) 1996-05-30 2006-01-24 F. Hoffmann-La Roche Ag Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii)
US5922685A (en) 1996-06-05 1999-07-13 Powderject Vaccines, Inc. IL-12 gene therapy of tumors
ES2176574T3 (es) * 1996-09-03 2002-12-01 Gsf Forschungszentrum Umwelt Utilizacion de anticuerpos bi y triespecificos para la induccion de inmunidad tumoral.
US5994104A (en) 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ES2187954T3 (es) 1997-04-11 2003-06-16 Searle & Co Anticuerpos anti-integrina avb3 antagonistas.
AU8182298A (en) * 1997-07-10 1999-02-08 Beth Israel Deaconess Medical Center Recombinant erythropoietin / immunoglobulin fusion proteins
DE69824039T2 (de) 1997-12-08 2005-08-18 Lexigen Pharmaceuticals Corp., Lexington Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
US20030105294A1 (en) 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
JP2002505086A (ja) * 1998-02-25 2002-02-19 レキシジェン ファーマシューティカルズ コーポレイション 抗体ベースの融合タンパク質の循環半減期の増強
PL343462A1 (en) 1998-04-15 2001-08-13 Lexigen Pharm Corp Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
RU2217168C2 (ru) * 1998-04-17 2003-11-27 Лексиген Фармасьютикэлс Корпорейшн Усиление иммунных ответов, опосредованных белками, слитыми из антитела и цитокина, посредством совместного введения ингибитора простагландина
AU3655899A (en) * 1998-04-20 1999-11-08 Regents Of The University Of California, The Modified immunoglobulin molecules and methods for use thereof
AU751823B2 (en) 1998-05-14 2002-08-29 Merck Patent Gmbh Fused protein
US6620382B1 (en) 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
EP1105427A2 (en) * 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
BR9913331A (pt) 1998-08-25 2001-05-15 Lexigen Pharm Corp Expressão e exportação de inibidores de angiogênese como imunofusinas
US6646113B1 (en) 1998-09-17 2003-11-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants
US6335176B1 (en) * 1998-10-16 2002-01-01 Pharmacopeia, Inc. Incorporation of phosphorylation sites
SK9432001A3 (en) * 1999-01-07 2003-02-04 Lexigen Pharm Corp Expression and export of anti-obesity proteins as Fc fusion proteins
KR100773109B1 (ko) 1999-05-06 2007-11-02 웨이크 포리스트 유니버시티 면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법
US6348192B1 (en) 1999-05-11 2002-02-19 Bayer Corporation Interleukin-2 mutein expressed from mammalian cells
ATE369384T1 (de) * 1999-05-19 2007-08-15 Emd Lexigen Res Ct Corp Expression und export von interferon-alpha proteinen als fc fusionsproteine
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
MXPA02000962A (es) * 1999-07-29 2002-07-02 Medarex Inc Anticuerpos monoclonales humanos para her2/neu.
BR0013231A (pt) * 1999-08-09 2002-07-23 Lexigen Pharm Corp Complexos citocina-anticorpo múltiplos
EP1228214A2 (en) 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
US20050202538A1 (en) 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
ES2269366T3 (es) 2000-02-11 2007-04-01 Merck Patent Gmbh Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos.
DE60121733T2 (de) * 2000-02-24 2007-08-09 Philogen S.P.A. Zusamensetzungen und Verfahren zur Behandlung von Angiogenese in pathologischen Schädigungen
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
US20020019342A1 (en) 2000-05-12 2002-02-14 Robert Bayer In vitro modification of glycosylation patterns of recombinant glycopeptides
DE60129695T2 (de) 2000-06-29 2008-06-05 Merck Patent Gmbh Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
JP2004525621A (ja) * 2001-01-18 2004-08-26 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング グルコセレブロシダーゼ活性を有する二機能性融合タンパク質
RU2363707C2 (ru) * 2001-02-19 2009-08-10 Мерк Патент Гмбх Искусственные белки с пониженной иммуногенностью
EP1998266A3 (en) 2001-02-19 2009-02-11 Merck Patent GmbH Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity
BR0207854A (pt) 2001-03-07 2004-08-24 Merck Patent Gmbh Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
DE60239454D1 (de) 2001-05-03 2011-04-28 Merck Patent Gmbh Rekombinanter, tumorspezifischer antikörper und dessen verwendung
ES2381025T3 (es) 2001-12-04 2012-05-22 Merck Patent Gmbh Inmunocitocinas con selectividad modulada
JP4494977B2 (ja) 2002-12-17 2010-06-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質
US20050069521A1 (en) 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
CA2551915C (en) 2003-12-30 2015-06-23 Merck Patent Gesellschaft Mit Beschraenkter Haftung Il-7 fusion proteins
PT1699821E (pt) 2003-12-31 2012-08-23 Merck Patent Gmbh Proteína de fusão fc-eritropoietina com farmacocinética melhorada
WO2005070967A2 (en) 2004-01-22 2005-08-04 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
RU2437893C2 (ru) 2004-12-09 2011-12-27 Мерк Патент Гмбх Варианты il-7 со сниженной иммуногенностью
US20070104689A1 (en) 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
JP2009521912A (ja) 2005-12-30 2009-06-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 低減された免疫原性を有する抗ｃｄ１９抗体
JP2009521909A (ja) 2005-12-30 2009-06-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ＩＬ−６とＩＬ−６Ｒαの複合体のｇｐ１３０への結合を阻害する抗ＩＬ−６抗体
PT1966238E (pt) 2005-12-30 2012-07-31 Merck Patent Gmbh Uso de hsp70 como um regulador de atividade enzimática
AU2007229698B9 (en) 2006-03-24 2012-11-08 Merck Patent Gmbh Engineered heterodimeric protein domains
JP2009542592A (ja) 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法

Also Published As

Publication number Publication date
CN1330664C (zh) 2007-08-08
KR100900176B1 (ko) 2009-06-02
PT1366067E (pt) 2012-11-29
CA2440221A1 (en) 2002-09-19
KR20030092015A (ko) 2003-12-03
RU2003129528A (ru) 2005-04-10
EP1366067B1 (en) 2012-09-26
KR20090010127A (ko) 2009-01-28
AU2002248571B2 (en) 2007-01-18
WO2002072605A3 (en) 2002-11-14
WO2002072605A2 (en) 2002-09-19
DK1366067T3 (da) 2012-10-22
JP4234438B2 (ja) 2009-03-04
CA2440221C (en) 2013-02-05
US20060263856A1 (en) 2006-11-23
US20030044423A1 (en) 2003-03-06
US8066994B2 (en) 2011-11-29
US7148321B2 (en) 2006-12-12
ES2393733T3 (es) 2012-12-27
PL206701B1 (pl) 2010-09-30
EP1366067A4 (en) 2005-07-20
CN1509293A (zh) 2004-06-30
JP2004525630A (ja) 2004-08-26
HUP0303428A2 (hu) 2004-01-28
EP1366067A2 (en) 2003-12-03
MXPA03008031A (es) 2003-12-04
PL366981A1 (en) 2005-02-07
ZA200307792B (en) 2004-07-06

Similar Documents

Publication Publication Date Title
BR0207854A (pt) Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
BR0208207A (pt) Redução da imunogenicidade das proteìnas de fusão
BR9903204A (pt) Composição cosmética e/ou dermatológica, utilização de uma emulsão água-em-óleo e processo de coloraçao artificial da pele
BRPI0311516A8 (pt) Composição de xampu de condicionamento e seu método de preparo
BR0305074A (pt) Composições cosméticas com alta afinidade
BR9910023A (pt) Conjugados de poliol-ifn-beta
BR9908015A (pt) Composições que compreendem vìrus e métodos para concentração de preparações de vìrus
BR9708387A (pt) Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
HK1033582A1 (en) Antibodies to death receptor 4 (dr4) and uses thereof
EA199700143A1 (ru) Способ и композиция ждя липидизации гидрофильных молекул
BR0316048A (pt) Copolìmero com estrutura controlada e utilização de um copolìmero
BR9915679A (pt) Composições e métodos para aumentar a mineralização óssea
BR0212035A (pt) Fator ix modificado
BR0009323A (pt) Anticorpos humanos que ligam a il-12 humana e métodos para a produção
BR0014486A (pt) Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
EA200400815A1 (ru) Контролируемый синтез зипразидона и его композиции
BR0011030A (pt) Composições de cicloporina substancialmente livre de óleo
TR199802394A2 (xx) Proteinleri stabilize etmek i�in geli�tirilmi� proses.
ATE381530T1 (de) Cycloalkancarbonsäurederivate als duftstoffe mit moschuscharakter
DE69504808T3 (de) Corticotropin freisetzende rezeptoren des faktor 2
BR0315178A (pt) Eritropoietina: remodelagem e glicoconjugação de eritropoietina
DK0865271T4 (da) Anvendelse af 2-ethylhexyl alfa-cyano-beta, beta-diphenylacrylat med henblik på at forbedre stabiliteten over for lys af p-methylbenzyliden-kamfer
BR0303912A (pt) Composição para o condicionamento, composição para o condicionamento durável, método para o condicionamento, método para o condicionamento durável, método para o cuidado ou tratamento e kit para o cuidado, tratamento, condicionamento ou condicionamento durável
BR9710849A (pt) Vacina contendo uma peróxi-redoxina e/ou uma beta-tubulina.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011.